Sanofi is celebrating a pair of regulatory successes for drugs that will be the first treatments to be approved for two rare diseases, acid sphingomyelinase deficiency (ASMD) and eosinophilic esophagitis (EoE).
First up is another approval in the US for the mega-blockbuster Dupixent (dupilumab) which has just received the green light...






